These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26056042)

  • 21. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
    Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.
    Koç E; Caner V; Büyükpınarbaşılı N; Tepeli E; Türk NS; Ozan Çetin G; Bağcı G
    Mol Biol Rep; 2012 Jan; 39(1):375-80. PubMed ID: 21553053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer.
    Lee SY; Choi JE; Jeon HS; Hong MJ; Choi YY; Kang HG; Yoo SS; Lee EB; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Son JW; Park JY
    Ann Oncol; 2015 Jun; 26(6):1142-1148. PubMed ID: 25716425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
    Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients.
    Park SY; Hong YC; Kim JH; Kwak SM; Cho JH; Lee HL; Ryu JS
    Med Oncol; 2006; 23(4):489-98. PubMed ID: 17303907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer.
    Lee SY; Jin CC; Choi JE; Hong MJ; Jung DK; Do SK; Baek SA; Kang HJ; Kang HG; Choi SH; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Cho S; Yoo SS; Lee J; Cha SI; Kim CH; Lee YM; Lee IK; Jheon S; Park JY
    Sci Rep; 2016 Oct; 6():35603. PubMed ID: 27767175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer.
    Li C; Liu M; Yan A; Liu W; Hou J; Cai L; Dong X
    Tumour Biol; 2014 Dec; 35(12):12707-12. PubMed ID: 25217323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis.
    Zhu J; Hua RX; Jiang J; Zhao LQ; Sun X; Luan J; Lang Y; Sun Y; Shang K; Peng S; Ma J
    PLoS One; 2014; 9(5):e97616. PubMed ID: 24841208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
    Carcereny E; Ramirez JL; Sanchez-Ronco M; Isla D; Cobo M; Moran T; de Aguirre I; Okamoto T; Wei J; Provencio M; Lopez-Vivanco G; Camps C; Domine M; Alberola V; Sanchez JM; Massuti B; Mendez P; Taron M; Rosell R
    Lung Cancer; 2010 Jun; 68(3):491-7. PubMed ID: 19733931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
    Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
    Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.
    Zhang ZY; Tian X; Wu R; Liang Y; Jin XY
    Asian Pac J Cancer Prev; 2012; 13(6):2583-6. PubMed ID: 22938424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
    Okuda K; Sasaki H; Hikosaka Y; Kawano O; Yukiue H; Yano M; Fujii Y
    J Surg Res; 2011 Jun; 168(2):206-12. PubMed ID: 20070981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.
    Zhang S; Li Q; Zhang Q; Wang J; Zhang H; Zhang Z; Wang Q; Yang X; Gu Y; Zhang H
    Int J Biol Markers; 2010; 25(3):141-9. PubMed ID: 20878620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.
    Simon GR; Sharma S; Cantor A; Smith P; Bepler G
    Chest; 2005 Mar; 127(3):978-83. PubMed ID: 15764785
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Chaszczewska-Markowska M; Kosacka M; Chryplewicz A; Dyła T; Brzecka A; Bogunia-Kubik K
    Anticancer Res; 2019 Jun; 39(6):3269-3272. PubMed ID: 31177178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.